Navigation Links
Merck and Takeda to collaborate in the sale of Cancer drug Matuzumab

Merck Pharmaceuticals from Germany and Takeda Pharmaceuticals from Japan to colloborate in marketing of Merck's cancer drug Matuzumab.

Matuzumab is developed by Merck which is in its Phase II // clinical tiral. Takeda Pharmaceuticals will sign agreement with Merck to give royalty and sale benefits from the sale of Matuzumba. Takeda will pay 60 million euros to Merck with an addition of royalty.

"Merck KGaA and Takeda Pharmaceutical have entered into a co-development and co-commercialization agreement for Merck's Matuzumab," the German company said in a statement.

Matuzumab was developed by Merck and currently is in Phase II clinical trials in patients with lung, gastric and colorectal cancers. Merck said it had decided to enter into cooperation with Takeda "in order to put more resources and expertise toward this important product". "Takedas experience and commitment in the field of oncology makes it a perfect fit with Merck, " it said.

"This collaboration with Takeda, Japans largest pharmaceutical company, will allow us to move ahead quickly with development and commercialisation of this potentially important product for cancer patients," said the head of Merck Ethical Pharmaceuticals, Elmar Schnee.

Source: Indo-Asian News Services
'"/>




Page: 1

Related medicine news :

1. E Merck introduces Livogen Z with zinc sulphate
2. Merck to pay $ 253.5 million to Vioxx victim family
3. Judgment In Favor Of Merck For Vioxx Drug
4. Merck, ICMR to conduct joint trials on cervical cancer vaccine
5. Merck in the Dock Due To Vioxx
6. Merck Says Januvia Effective In Type 2 Diabetes
7. Dr Reddys Launches Generic Version Of Mercks Proscar Tablets
8. Patency On Two Drugs From Merck & Pfizer’s To Expire Soo
9. Developing Nations to Get Gardasil at Lesser Rates from Merck Soon
10. Acid Test - Glaxos Cervarix, and Mercks Gardasil, Compete
11. Ranbaxy in Fray to Buy Mercks Generic Drugs Unit
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/25/2017)... ... 25, 2017 , ... FDAnews Expert Insight Series:, Device Regulation ... – 3:00 p.m. ET, http://www.fdanews.com/deviceregulation      , FDA Commissioner Scott ... short months:, ,     The first device recall over cybersecurity (a ...
(Date:9/25/2017)... ... September 25, 2017 , ... The Byron Eaton Agency, ... the central Alabama region, is organizing a local charity drive to send money and ... 11 trillion gallons of water have fallen on Houston as a result of Hurricane ...
(Date:9/25/2017)... , ... September 25, 2017 , ... ... the launch of its new website. No need to be concerned about ... answer. Go to welldonedesigns.com where all orders are printed and shipped within 5-10 ...
(Date:9/25/2017)... , ... September 25, 2017 , ... ... and development solutions for drugs, biologics and consumer health products, today announced that ... development and validation of bioassays at two upcoming conferences. , At the BEBPA ...
(Date:9/25/2017)... ... 25, 2017 , ... NCPDP Foundation , a 501(c)(3) ... awarded a $40,000 grant to Johns Hopkins Medicine to address patient safety risk ... to electronically cancel a prescription already submitted to a pharmacy. Studies indicate that ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... 2017 NuvoAir (formerly called Pond Healthcare ... a partnership with Novartis Pharma AG to distribute NuvoAir,s spirometry ... the leading mobile spirometry platform and Novartis, commitment to address ... ... ...
(Date:9/6/2017)... 2017  Robert G. Szewc, M.D., is recognized by ... recognition of his contributions to the Medical field.      ... at the practice of Kidney and Hypertension Specialists, which ... hypertension solutions. He has worked in this position since ... as well as expertise in kidneys, hypertension, chronic disease ...
(Date:9/6/2017)... 6, 2017 NeuroRx, a clinical stage biopharma company ... Behavior (ASIB), has been granted Fast Track status by the ... NRX-100 (ketamine HCl) followed by NRX-101 (D-cycloserine + lurasidone). The ... of this sequential therapy targeting patients who are admitted to ... ...
Breaking Medicine Technology: